ALPMF (Astellas Pharma) Insider Ownership: 0.00 % (As of Aug. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALPMF Astellas Pharma Inc ALPMF
77 GF Score
Price $13.05
GF Value $14.36
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Astellas Pharma Insider Ownership?

Astellas Pharma ALPMF +22.99% 77 Insider Ownership is 0.00 % as of Aug. 07, 2026. GuruFocus rates ALPMF with a GF Score™ of 77/100 and a GF Value™ of $14.36 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Astellas Pharma's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Astellas Pharma's Institutional Ownership is 42.59%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Astellas Pharma's Float Percentage Of Total Shares Outstanding is 0.00%.

Astellas Pharma Insider Ownership Historical Data

* Premium members only.

The historical data trend for Astellas Pharma's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma Insider Ownership Chart

Astellas Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Insider Ownership
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Astellas Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Insider Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ALPMF
77GF Score
Astellas Pharma Inc ALPMF
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Astellas Pharma Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 0.00 % mean?
Astellas Pharma (ALPMF) has a Insider Ownership of 0.00 % as of Aug. 07, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Astellas Pharma and its competitors.
Is Astellas Pharma's Insider Ownership too high?
Astellas Pharma's current Insider Ownership is 0.00 %. Overall, Astellas Pharma has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Insider Ownership compare to LLY and JNJ?
Astellas Pharma's Insider Ownership of 0.00 % can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Drug Manufacturers company?
A good Insider Ownership depends on the Drug Manufacturers industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Astellas Pharma and its competitors. Astellas Pharma's current Insider Ownership is 0.00 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Modestly Overvalued. The stock's GF Value™ is $14.36, compared to a current price of $13.05 — trading 9.1% below its estimated fair value. The current Insider Ownership is 0.00 %. Astellas Pharma's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current Insider Ownership is 0.00 % as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astellas Pharma (ALPMF) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued. The current stock price of $13.05 is trading 9.1% below its estimated GF Value™ of $14.36. GuruFocus considers Astellas Pharma to be Modestly Overvalued.

Key valuation signals for ALPMF:

  • Insider Ownership: 0.00 %
  • GF Value™: $14.36 vs. price of $13.05 (9.1% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Astellas Pharma Business Description

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
77GF Score

Get the complete analysis for ALPMF

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.05
Price
$14.36
GF Value